VC
Value Add VC
⚡
Home
Pulse
🧰
Tools
📝
Blog
🤝
Sponsor
Search
🗂️
Categories
🛠️
Tools
Intelligence
/
Investors
/
Leaps by Bayer
Leaps by Bayer
Venture capital firm
Portfolio
1 total
Celea Therapeutics
Co-Investors
2
PureTech Health · 1 shared
RA Capital · 1 shared
Latest Pulse
Pulse coverage →
Jul 2, 2026
Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug
Celea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.
→
Suggest a correction